H3 receptor


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.
Related to H3 receptor: H1 receptor, H2 receptor, H3 receptor antagonists

H3 receptor

, histamine H3 receptor
A presynaptic receptor in the CNS that controls the release of histamine and other neurotransmitters, including acetylcholine, dopamine, and norepinephrine. It influences arousal and sleep, cognition, attention, and other body functions.

H3 receptor

A presynaptic receptor in the central nervous system that controls the release of histamine and other neurotransmitters, including acetylcholine, dopamine, and norepinephrine. It influences arousal and sleep, cognition, attention, and other body functions.
Synonym: histamine H3 receptor
See also: receptor
References in periodicals archive ?
Although, these studies have indicated that histaminergic receptors could have a modulatory effect on memory processes, there have been no reports about the effects of histamine mediated by H3 receptors present in the cerebellum on the consolidation of memory using repeated testing in an EPM.
The first paper describes the utility of distinct histamine H3 receptor agents in the regulation of appetite and weight gain in preclinical models.
Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.
GT2331 is a selective histamine H3 receptor antagonist being developed by Gliatech for potential use in central nervous system diseases involving attention/learning or sleep disorders.
The histamine H3 receptor is predominantly located in the Central Nervous System (CNS), where it regulates the synthesis and release of the neurotransmitter histamine.
Nasdaq: GLIA) today announced the initiation of Phase I human clinical trials for GT 2331, its selective histamine H3 receptor antagonist, which may be useful in central nervous systems (CNS) disorders involving disturbances in arousal or cognitive function.
Nasdaq: GLIA) today announced that it has been awarded a $100,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke for research directed towards cloning the human histamine H3 receptor.
Nasdaq: GLIA) today announced that researchers at Stanford University School of Medicine have identified wake promoting or vigilant-promoting properties in Gliatech's novel histamine H3 receptor antagonists.